Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...
Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...
In December 2025, Celcuity Inc. reported updated Phase 3 VIKTORIA-1 trial results at the San Antonio Breast Cancer Symposium, showing gedatolisib-based regimens improved progression-free survival and ...
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...
First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and global clinical development strategy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback